Navigation Links
Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference
Date:11/2/2007

and/or ARB received (as a percentage of the maximum FDA recommended dose). The benefit of XL784 compared to placebo increased with increasing dose of ACEi and/or ARB. In the subgroup of subjects treated with maximum recommended doses of ACEi and/or ARB, the difference between XL784 and placebo was 23% (p=0.13) for the primary analysis population.

XL784 was generally well-tolerated, with fewer subjects reporting adverse events in the XL784 group (77%) than in the placebo group (85%). Serious adverse events (SAEs) were reported by 9.5% of subjects in the XL784 group and by 11% of subjects in the placebo group. No SAEs in the XL784 group were considered to be related to study drug.

"We are pleased to report the data from the XL784 trial in patients with diabetic nephropathy," said George A. Scangos, PhD, president and chief executive officer of Exelixis. "While the trial did not meet its primary endpoint, various subgroup analyses suggest that the compound may have the potential to benefit patients with this disease. We submitted the XL784 data package to GSK on October 22, 2007 and expect to communicate future plans for XL784 once GSK has reached a decision on its interest in further developing the compound."

The previously announced briefing to be held today in conjunction with the presentation of the data for XL784 has been cancelled. However, we expect to discuss the data during the live webcast of our third quarter financial results and general business updates to be held on Monday, November 5, 2007 at 2:00 p.m. PST/5:00 p.m. EST. The webcast may be accessed in the Event Calendar page under Investors at http://www.exelixis.com. In addition, we will discuss the data for XL784 at our Third Annual R&D Day on December 5, 2007 to be held in New York.

About XL784

XL784 is the first small molecule compound developed by Exelixis using its proprietary drug discovery engine. The compound is a
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... - New Solution That Makes JINS MEME,s ... Co., Ltd. will launch JINS MEME "ACADEMIC PACK" in late ... $5,000 (without tax /including two pairs of JINS MEME and ... solution of "JINS MEME" to academic researchers, and it enables ... electrooculography and six-axis sensors without API. (*Physiological data that can ...
(Date:11/26/2014)... 26, 2014  Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... conferences. On Tuesday, December 2, the company ... Jaffray Healthcare Conference.  D. Keith Grossman , President ... the company beginning at 11:30 a.m., Eastern Standard Time ...
(Date:11/26/2014)... ANDOVER, Mass. , Nov. 26, 2014 /PRNewswire/ ... AEX: PHIA) today announced expanded availability of ... including DuraDiagnost, DigitalDiagnost, MobileDiagnost wDR, MobileDiagnost Opta[i] , ... of these solutions now available in the U.S., ... global markets, the portfolio offers Philips, customers innovative ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Thoratec Announces Presentations At Investor Conferences For December 2014 2Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3
... Possible by Early Investment by Cystic Fibrosis ... ... Gilead Sciences,Inc., one of the world,s largest biopharmaceutical companies, and Parion,Sciences, ... a compound that could become an important,new drug in treating the ...
... DIEGO, Aug. 16 ADVENTRX Pharmaceuticals,Inc. (Amex: ... development company,focused on commercializing proprietary product candidates ... today announced that the U.S. Food and,Drug ... for ANX-510,or CoFactor(R) injection, which is currently ...
Cached Medicine Technology:Promising Cystic Fibrosis Compound on Track for Development 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 3
(Date:11/27/2014)... 2014 “Wekho” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers ... , An interesting new way to travel and experience the ... It’s called Wekho and it’s a free geolocation app ...
(Date:11/27/2014)... This is a professional and in ... an overview analysis, the report introduces Insulin basic ... industry overview, policy analysis, and news analysis, etc. ... information on policy, plans for Insulin Market product ... more. , This report also provides ...
(Date:11/27/2014)... 2014 At The Little Gym, we ... came as no surprise when a recent study confirmed ... success. The Journal of Pediatrics found that ... tasks during the school years may be important not ... The study monitored two groups of children; those that ...
(Date:11/27/2014)... 2014 The Emerald Cup 2014 Competition ... At This Year’s Entries | SKUNK Magazine – Proudly ... Two At Their Resort, Pure Garden, In Negril, Jamaica ... Hempcon, The Emerald Cup is presented by locals, for ... of California’s original cannabis industry." – SFGate, Smell The ...
(Date:11/27/2014)... November 27, 2014 In addition to ... an important gift home this holiday season and become ... disease. Visiting with relatives over the holidays may raise ... members. Although some change in cognitive ability can occur ... of normal aging. Recognizing the difference between normal aging ...
Breaking Medicine News(10 mins):Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 2Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 3Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 4Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 2Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 3Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 4Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 5
... Athens, Ga. - Pharmaceutical companies and universities are racing to ... RNA interference to treat a host of diseases. Now, a ... powerful tool: Researchers at the University of Georgia have demonstrated ... as a tool in the development of vaccines. , ...
... Dec. 10 /PRNewswire/ - Over 830 staff members are ... District,s newest fitness challenge. The 322 mile virtual race ... online challenge and it,s proving successful with less work ... Lee County School District has delivered fitness ...
... A University of British Columbia geneticist has discovered a gene ... uveal melanoma. , Catherine Van Raamsdonk, an assistant professor of ... team of researchers, have discovered a genetic mutation in a ... cent of the cases of uveal melanoma. , The findings, ...
... survey cites misperceptions regarding need for vaccination and a lack of ... , ... Bethesda, MD (PRWEB) December 10, 2008 -- A ... one-third (29.6 percent) have been vaccinated against the flu this season. ...
... superior to vitamin supplementation for cancer prevention. , ... ... of announcements two weeks ago that vitamin supplements A thru E ... more medical announcements with the same conclusions regarding prostate cancer. While ...
... 10 Markel Corporation is,pleased to announce the launch ... product. DataBreach(SM) helps businesses manage,risk associated with their reliance ... in their custody or care. , ... the increase in identity theft,that has been plaguing businesses ...
Cached Medicine News:Health News:Study first to show that RNA interference can facilitate vaccine development 2Health News:Study first to show that RNA interference can facilitate vaccine development 3Health News:Lee County School District online wellness program inspires employees to walk 200 million steps in 2 months 2Health News:UBC researchers discover gene mutation that causes eye cancer 2Health News:Mid-Season Flu Immunization Rates are Too Low 2Health News:Mid-Season Flu Immunization Rates are Too Low 3Health News:Mid-Season Flu Immunization Rates are Too Low 4Health News:Mid-Season Flu Immunization Rates are Too Low 5Health News:Treadmill Desks More Effective in Decreasing Prostate Cancer Risks Than Vitamin and Antioxidant Supplements 2Health News:Markel Corporation Announces New DataBreach(SM) Privacy Liability Coverage 2
... For treatment of carpal tunnel syndrome, mild ... following cast removal. The perforated suede ... the wrist, wicking away moisture for long ... metal splint prevents painful wrist flexion, and ...
... orthotic elbow system that can be used in ... proximal ulnar fractures or post reconstructive surgery where ... highly flexible system that provides you with a ... that best fits your patients needs. Two ...
A lightweight soft good with rigid elbow protection. Designed by medical professionals with your needs in mind. Provides elbow stability for mild to moderate medial/lateral and hyperextension injurie...
Worn by many professional athletes, EpiTrain is our most popular elbow support....
Medicine Products: